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Non-invasive ventilation in patients with an altered level 
of consciousness. A clinical review and practical insights
Abstract
Non-invasive ventilation has gained an increasingly pivotal role in the treatment of acute hypoxemic and/or hypercapnic respira-
tory failure and offers multiple advantages over invasive mechanical ventilation. Some of these advantages include the preserva-
tion of airway defense mechanisms, a reduced need for sedation, and an avoidance of complications related to endotracheal 
intubation.
Despite its advantages, non-invasive ventilation has some contraindications that include, among them, severe encephalopathy.
In this review article, the rationale, evidence, and drawbacks of the use of noninvasive ventilation in the context of hypercapnic 
and non-hypercapnic patients with an altered level of consciousness are analyzed.
Key words: non-invasive ventilation, altered consciousness, encephalopathy, coma
Adv Respir Med. 2020; 88: 233–244
Advances in Respiratory Medicine 2020, vol. 88, no. 3, pages 233–244
234 www.journals.viamedica.pl
Introduction
The utility of non-invasive ventilation (NIV) 
has been fully proven and well documented in 
several categories of patients with acute respi-
ratory failure (ARF) [1–3]. Recent ERS/ATS and 
ISCCM guidelines reported a high level of evi-
dence in favor of the use of NIV in acute acidic 
hypercapnic respiratory failure due to a COPD 
exacerbation, in acute pulmonary edema, in 
immunosuppressed hosts, and as a facilitating 
tool for transitioning from invasive ventilation 
to spontaneous breathing [4, 5]. 
By preventing endotracheal intubation (ETI), 
NIV confers many advantages over invasive me-
chanical ventilation (IMV). NIV is more comfor-
table and does not require the use of sedation in 
most cases [6]. It also allows patients to continue 
oral nutrition. The non-invasive interface allows 
positive pressure to be delivered while keeping 
the airway patent, thus preserving natural defense 
mechanisms. As such, NIV reduces morbidity and 
mortality by avoiding many complications asso-
ciated with IMV including nosocomial ventila-
tor-associated pneumonia, sepsis, and additional 
infectious sequelae [7]. 
Although NIV is an effective treatment, there 
are important limitations and contraindications 
to its use. In 2001, the International Consensus 
Conference on NIV [8] recommended against its 
use in the setting of cardiac or respiratory arrest, 
hemodynamic instability, unstable cardiac arrhy-
thmias, severe encephalopathy (Glasgow coma 
scale < 10), severe upper gastrointestinal ble-
eding, facial surgery or trauma, upper airway ob-
struction, and in patients who are at high risk for 
aspiration who are unable to protect their airway 
or to cooperate or clear respiratory secretions.
Most studies use the Glasgow coma scale 
(GCS) or the Kelly-Matthay score (KMS) to assess 
the level of consciousness. Although GCS is the 
tool which has been mostly used in the clinical 
setting, this 15-point scoring system in which 
a lower score corresponds to a lower level of 
consciousness was originally developed to assess 
and monitor changes in the level of consciousness 
after head trauma [9]. The 6-level KMS is a tool 
specifically designed to evaluate neurological 
alterations in patients ventilated in the intensive 
care unit (ICU) [10]. With the KMS, a higher score 
corresponds to a lower level of consciousness.
In this article, we reviewed the rationale, 
evidence, and pitfalls regarding use of NIV in hy-
percapnic and non-hypercapnic ARF in patients 
with an altered level of consciousness. 
Material and methods
We performed a search in the PubMed Na-
tional Library with the keywords “non-invasive 
ventilation”, “hypercapnic”, “hypoxemic”, “al-
tered consciousness”, “encephalopathy”, and 
“coma”. Articles were selected according to their 
relevance to the topic of this review. Backward 
reference searching from selected articles was 
also performed. In addition, other articles were 
reviewed and included based on the authors’ 
judgment of their relevance. Studies were limited 
to the English language.
Rationale for NIV use in patients 
with hypercapnic ARF encephalopathy 
The pathophysiology of hypercapnic ence-
phalopathy may be explained by the acidosis of 
cerebrospinal fluid and brain interstitial tissue. 
Acute respiratory acidosis has a greater impact on 
cerebrospinal fluid pH than metabolic acidosis 
does because CO2 crosses the blood-brain barrier 
easily and quickly due to its high liposolubility. 
Accordingly, symptoms of hypercapnic ence-
phalopathy (i.e. cognitive defects, delirium, and 
coma) correlate more strongly with changes in 
cerebrospinal pH than with those in arterial pH 
and/or PaCO2 [11]. Although several pulmonary 
and extrapulmonary factors are involved as well, 
it is safe to assume that by normalizing arterial 
pH by diminishing arterial PaCO2, cerebrospinal 
pH can be normalized as well.
The rationale for using NIV in hypercapnic 
encephalopathy is based on the reduction in 
PaCO2 levels  and its advantages over IMV. Firstly, 
its efficacy on respiratory muscles, improvement 
in gas exchange, and in in-hospital mortality in 
patients with respiratory acidosis due to acute 
exacerbations of COPD with the use of NIV is 
comparable to that of IMV [11, 12]. 
Secondly, the absence of ETI and other inva-
sive devices reduces the risk of ventilator-asso-
ciated pneumonia [13]. 
Thirdly, the risk of gastric distension and 
aspiration is probably overestimated due to 
the physiological barriers of the upper (resting 
pressure between 60–139 cm H2O) [14] and lower 
sphincters (resting pressure between 14–41 cm 
H2O) [15]; it is uncommon to use NIV pressures 
higher than 30 cm H2O, thus minimizing this risk.
Fourthly, NIV has an important role as a form 
of salvage therapy in frail patients with end-stage 
chronic respiratory failure and do-not-intubate or-
ders, especially in cases of hypercapnic coma [16].
Gil Gonçalves et al., Non-invasive ventilation in patients with an altered level of consciousness
235www.journals.viamedica.pl
Finally, NIV has been shown to reduce the 
length of ICU and hospital stays and can lead to 
more effective resource utilization [17]. These im-
portant quality metrics translate into improved pa-
tient outcomes and reduced financial burden [11].
Current evidence for the use of NIV 
in hypercapnic ARF encephalopathy
We reviewed the published literature exami-
ning the use of NIV in patients with hypercapnic 
encephalopathy. Most reports showed an impro-
vement in the GCS score within a few hours after 
NIV initiation (Figure 1, Table 1).
Corrado et al. [18] were the first to evalu-
ate patients with hypercapnic coma of various 
etiologies treated with NIV (iron lung). In their 
study, the mean arterial pH was 7.13 ± 0.3 and 
PaCO2 was 112 ± 21 mm Hg. Of the 150 patients 
analyzed, treatment was successful in 70%, ran-
ging from 0% in patients with a GCS of 3 to 85% 
with a GCS of 8. Five patients had aspiration 
complications, but all were successfully treated 
without intubation. Through multivariate analy-
sis, a GCS of ≤ 6 and age ≥ 70 years were the only 
variables associated with NIV failure.
In a study by Briones et al. [19], the effecti-
veness of positive pressure NIV compared to IMV 
was assessed in two cohorts of twelve patients 
each with similar baseline characteristics (GCS 
< 8, arterial pH < 7.25, APACHE II scores). Both 
groups presented to the Emergency Department 
with severe hypercapnia secondary to an acute 
exacerbation of COPD. NIV was considered suc-
cessful when the following parameters were met: 
respiratory rate of < 24 breaths/min, heart rate of 
< 90 beats/min, improvement in consciousness 
level (GCS 15/15), and compensated arterial pH 
with adequate oxygen saturation at room air or 
with the use of a low percentage of inspired oxy-
gen (FiO2 < 31%). The authors identified a lower 
30 day mortality (16.7% vs 33.3%, p = 0.01), fewer 
days on mechanical ventilation (3.6 ± 1.1 vs 5.6 ± 
1.2, p = 0.006), and a shorter hospital stay (6.5 ± 
1.9 vs 11.1 ± 4.7 days, p = 0.001) in the NIV (vs 
IMV) group, but no differences in survival at 
6 months (80% vs 71.4%, p = 0.80). This study 
noted that improvements in PaCO2, pH, and GCS 
measured at 3 hours after NIV initiation were 
predictive of continued success of NIV therapy. 
Important differences, measured and unmeasu-
red, may have existed between the cohorts and 
may in part explain the observed differences in 
outcomes.
Diaz et al. [20] prospectively examined pa-
tients with hypercapnic coma (GCS ≤ 8) secondary 
Figure 1. Flowchart of the study selection process for using non-invasive ventilation in hypercapnic acute respiratory failure encephalopathy
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Table 1. Current evidence for using NIV in hypercapnic ARF encephalopathy
Author, year Patients and aim of 
the study
Level of 
consciousness
Type of study Results Limitations
Lemyze 2019 
[16]
86 DNI patients, NIV 
in hypercapnic coma 
vs NIV in hypercapnic 
ARF without coma
Comatose group with 
KMS ≥ 5
Prospective observa-
tional case-control
study
70% survived to 
hospital discharge 
and half survived 6 
months, with similar 
outcomes to
controls
Selection bias could 
not be ruled out
Corrado 1996 
[18]
150 patients, evalu-
ate NIV (iron lung)
success in
hypercapnic coma
All GCS 3–8 Retrospective, uncon-
trolled study
NIV failure in 30%. 
GCS ≤ 6
had negative prog-
nostic value
Retrospective study, 
limited availability of 
iron lung
Briones 2008 
[19]
24 patients, NIV vs 
IMV in hypercapnic 
coma
All GCS < 8 Prospective interven-
tional study
Less days on me-
chanical ventilation, 
days of stay and 30-
day mortality
Small group of pa-
tients
Diaz 2005 [20] 958 patients,
determine NIV suc-
cess
in hypercapnic coma 
vs
NIV while awake
All GCS ≤ 8 Prospective, open, 
noncontrolled study
No increase in failure 
or mortality relative 
to non-comatose 
patients
Observational design, 
lack of control sub-
jects
Scala 2007 [21] 40 patients, NIV vs 
IMV in hypercapnic 
encephalopathy
All KMS ≥ 3 Prospective matched 
case-control
study
Shorter duration of 
mechanical ventila-
tion and lower rate of 
complications. Mor-
tality similar in both 
groups
Case-control design 
and lack of random-
ization
Zhu 2007 [22] 68 patients,
evaluate the effec-
tiveness and safety 
of NIV for severe 
hypercapnic enceph-
alopathy
GCS < 10 vs GCS 
≥ 10
Prospective 
case-control study
Similar results in 
hospital mortality and 
NIV success vs con-
trol group
Different levels of 
pressure support and 
NIV time between 
groups
Stefan 2015 [24] 2577 patients, com-
pare outcomes of 
acute exacerbation of 
COPD, NIV vs IMV
GCS in NIV group of 
15 (IQR 14–15)
Retrospective, mul-
ticenter cohort of 
prospectively collect-
ed data
Lower GCS was pre-
dictive of NIV failure
Patients received 
ventilatory support 
for an exacerbation 
of COPD and not nec-
essarily hypercapnic 
acidotic exacerbation
Confalonieri 2005 
[25]
1033 patients, assess 
the risk of NIV failure 
in acute exacerba-
tions of COPD
GCS 13.2 ± 2.3 Prospective study GCS ≤ 14 was pre-
dictive of NIV failure; 
main factor influenc-
ing the outcome was 
the pH value
Absent
Fan 2014 [26] 261 patients, mea-
sure cough
strength and out-
comes in acute ex-
acerbations of COPD 
on NIV
GCS 14.8±0.5 in NIV 
success vs GCS 13.8 
± 2.5 in NIV failure
Prospective observa-
tional study
APACHE II, semi-
quantitative cough 
strength score and 
total proteins were 
the only predictors of 
NIV failure
Accuracy of cough 
measurements
based on the clini-
cians’ experience
Wang 2017 [27] 164 patients, com-
pare NIV and IMV 
combined with a 
non-invasive strategy 
for clearing secre-
tions in hypercapnic 
encephalopathy
All KMS ≥ 3 Prospective cohort 
study
2 hours of NIV with 
clearance of secre-
tions
significantly improved 
KMS and arterial 
blood gases. Hospital 
mortality lower in the 
NIV group
Not a randomized 
controlled trial,
single-center study,
hospital setting be-
tween groups
differed, did not 
include an additional 
group
with NIV alone
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Scala 2010 [28] 30 patients, early 
fiberoptic bronchos-
copy during NIV vs 
IMV-based strategy in 
hypercapnic enceph-
alopathy
KMS 2–4 Prospective matched 
case-control study
Higher complication 
rates in the
IMV group.
Similar hospital mor-
tality, hospital lengths 
of stay, and duration 
of ventilation in the 
two groups
NIV application with 
the concomitant use 
of fiberoptic bron-
choscopy to remove 
secretions should be 
reserved for centers 
where all staff mem-
bers
have sufficient expe-
rience
Contou 2013 [51] 242 patients admit-
ted for
hypercapnic ARF, 
assess the rate
of NIV failure
Included
RASS < 0
Observational cohort 
study
Altered levels of 
consciousness at 
admission
had no influence on 
outcome
Retrospective, single 
unit, longstanding
experience in NIV 
practice
Briones 2013 
[52]
22 patients, BiPAP 
S/T vs AVAPS mode
All GCS < 10 Prospective interven-
tional match-con-
trolled study
Rapid improvement in 
arterial blood
gases and GCS in 
both groups
Small number of 
patients
Scala 2005 [53] 153 patients requiring 
NIV divided into 4 
groups, according to
level of conscious-
ness
Groups: KMS 1, KMS 
2, KMS 3 and KMS 
> 3
5-year case-control 
study with a prospec-
tive data collection
Significant improve-
ment in arterial blood 
gases and KMS in all 
groups after 1 to 2 
hours. NIV failure and 
90-day mortality sig-
nificantly increased 
with worse KMS
No randomization
Jatoi 2019 [54] 78 patients, predict 
NIV success in post-
TB sequelae
GCS 8.4 ± 2.1 in 
nonresponders vs 
GCS 9.4 ± 1.8 in 
responders
Single center, pro-
spective, cohort 
study
Lower GCS was a 
significant indepen-
dent predictor of
NIV failure
Single unit, no IMV 
group control, ab-
sence of long-term 
mortality or morbidity
Scarpazza 2013 
[55]
78 patients, assess 
NIV success in hyper-
capnic ARF
GCS 7.2 ± 1.5 in 
non-responsive 
patients vs GCS 9.7 
± 2.9 in respondive 
patients
Single center, pro-
spective, cohort 
study
Lower GCS was a 
significant indepen-
dent predictor of
NIV failure
Single unit, no IMV 
group control
van Gemert 2015 
[56]
50 COPD patients, 
assess risk factors in 
transition from NIV 
to IMV
GCS 9–15 Retrospective cohort 
study
Lower GCS at presen-
tation is
associated with the 
transition from NIV to 
IMV in COPD
patients with hyper-
capnic ARF
Retrospective study, 
small sample size
Ucgun 2006 [57] 151 patients, identify 
factors affecting 
mortality and intuba-
tion in
COPD patients
GCS 14.1 ± 1.4 in 
nonintubated vs GCS 
10.8 ± 3.4 in intu-
bated
Single center, pro-
spective study
Lower GCS was 
associated with intu-
bation
Small sample size, 
low rate of NIV ap-
plications, inclusion 
of pneumonia and 
heart failure leading 
to acute exacerbation 
of COPD
Kida 2012 [58] 42 patients, identify 
predictors of NIV suc-
cess in elderly
GCS 8.9 ± 2.4 in sur-
vivors vs 4.0 ± 1.7 in 
non-survivors
Single center, retro-
spective study
GCS < 9 was asso-
ciated with higher 
mortality
Retrospective study, 
small sample size
ARF — acute respiratory failure; AVAPS — average volume-assured pressure support; BiPAP — bilevel positive airway pressure; COPD — chronic obstructive pul-
monary disease; DNI — do not intubate order; GCS — Glasgow coma scale; ICU — intensive care unit; IMV — invasive mechanical ventilation; IQR — interquartile 
range; KMS — Kelly-Matthay score; NIV — non-invasive ventilation; RASS — Richmond Agitation-Sedation Scale; TB — tuberculosis
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to respiratory failure of various causes and treated 
with NIV. At the beginning of ventilatory therapy, 
arterial pH was 7.13 ± 0.06 and PaCO2 was 99 ± 
19 mm Hg. Improvements in pH, GCS, PaCO2, and 
PaO2/FiO2 within the first hour of NIV correlated 
with NIV success. A high rate of response to NIV 
was achieved in comatose patients with cardio-
genic pulmonary edema, COPD, and obesity. 
Subjects with acute respiratory distress syndrome 
(ARDS) and pneumonia had a higher probability 
of not responding to NIV. These findings support 
that NIV success may be related to the type and 
nature of the underlying disease.
Scala et al. [21] conducted a prospective 
matched case-control study comparing 40 pa-
tients with neurological impairment (KMS ≥ 3) se-
condary to an acute exacerbation of COPD treated 
with NIV or IMV. In this study, the mean arterial 
pH and PaCO2 in NIV patients was 7.22 ± 0.02 and 
88 ± 15 mm Hg. In the control group, these same 
parameters were 7.22 ± 0.05 and 90 ± 10 mm Hg. 
They noted that consciousness improved from 
a mean of 3.4 ± 0.6 to 2.1 ± 0.8 points in NIV 
patients after 2 hours of treatment, and to 1.6 ± 
1.0 at 24 hours. Compared to the IMV group, the 
NIV group showed a shorter duration of mecha-
nical ventilation and a lower complication rate 
due to fewer cases of nosocomial pneumonia and 
sepsis despite similar (25%) in-hospital mortality 
rates between groups.
In a case control study, Zhu et al. [22] com-
pared a group of 22 exacerbated COPD patients 
with GCS < 10 with a control group of 21 subjects 
with GCS ≥ 10. They noted similar rates of hospital 
mortality (14% vs 14%, p > 0.05) and NIV success 
(73% vs 68%, p > 0.05). However, pressure sup-
port, NIV time, and hospital length of stay were 
significantly higher in patients with GCS < 10.
These studies conclusively demonstrated 
that many of the consensus-based “absolute” 
contraindications to NIV should be viewed as 
“relative”, although an increase in failure rates 
can be expected in the most severe forms of hy-
percapnic encephalopathy. Additionally, severe 
complications from NIV are rare. However, most 
published series have been submitted by teams 
with extensive experience in ventilatory support, 
and it is difficult to know whether these results can 
be extrapolated to other groups with less expertise.
Current evidence against the use of NIV 
in hypercapnic ARF encephalopathy
By contrast, there is also evidence that NIV 
can be harmful in certain settings. Some studies 
demonstrate high rates of NIV failure in patients 
with low consciousness levels. In these particu-
lar patients who initially receive NIV and then 
experience NIV failure, there is a subsequent 
need for them to be intubated in order to undergo 
IMV, which results in them being more likely to 
die in the hospital [23, 24]. One possible reason 
for the increased mortality can be due to an 
inappropriate initial selection of NIV candidates 
and/or delay in ETI. 
In a study by Confalonieri et al, the risk of 
NIV failure in a large unselected population ad-
mitted to different hospital units with expertise 
in NIV was assessed. The authors used this data 
and built two risk charts for NIV failure; one at 
admission and the other after 2 hours. NIV failure 
occurred in 236 patients (22.9%); among those, 
142 died (13.7%). Risk factors for NIV failure 
included APACHE II score ≥ 29, GCS ≤ 14, pH 
< 7.25, and respiratory rate ≥ 30 breaths/minute. At 
admission, in a patient with pH < 7.25, APACHE 
II ≥ 29 and GCS ≤ 11, the chart shows a predicted 
risk of failure > 70%. This risk increases to 90% 
if the same parameters are kept after 2 hours [25].
In addition, there is data that suggest ad-
ditional harm in patients with excessive se-
cretions. Most COPD exacerbations are triggered 
by pulmonary infections, and exacerbations are 
usually associated with copious secretions. A pre-
vious study has reported that COPD patients 
with low cough strength were more likely to 
experience NIV failure (up to 80%) [26]. In selec-
ted scenarios, a reduction in NIV failure may be 
achieved by initiating early suction of secretions 
with bronchoscopy performed during NIV by an 
expert team [27, 28].  In a matched case-control 
study by Scala et al. [28], bronchoscopy was per-
formed 18.5 ± 6.9 minutes after NIV initiation 
and lasted 7.8 ± 3.1 minutes with the removal 
of 23 ± 18 mL of respiratory secretions. In these 
patients, although both KMS and cough efficiency 
significantly improved after two hours, NIV still 
failed in 3 of 15 patients (20%). Compared to the 
IMV group, hospital mortality, hospital length of 
stay, and duration of ventilation were similar to 
patients in the NIV group.
Finally, a lack of cooperation in agitated 
patients may limit NIV success [29]. Continuous 
infusion of a single sedative and analgesic titrated 
to obtain a “conscious sedation” may decrease 
patient discomfort and improve gas exchange, 
with no significant effects on respiratory drive 
or hemodynamic status [30]. However, larger and 
more controlled trials are needed to clarify the 
indications of sedation during NIV. 
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Rationale for NIV use in patients with hypoxemic 
ARF and an altered level of consciousness
In this section, we will consider non-hyper-
capnic patients with an altered level of conscio-
usness who have symptoms related to impaired 
mental function that appeared as a result of hy-
poxia and sepsis. Hypoxemic non-hypercapnic 
patients with an altered level of consciousness 
refers to a syndrome marked by cerebral dys-
function caused by brain hypoxia and ischemia 
due to hypoxemic ARF. Similarly, septic encepha-
lopathy is an impaired mental status syndrome 
with a clinical presentation ranging from clouded 
thinking/consciousness to deep coma as can be 
seen in patients with systemic inflammation. Pa-
thophysiologic hallmarks are thought to comprise 
diffuse neuroinflammation, vascular dysfunction, 
and neurotransmitter imbalances leading to direct 
cellular neuronal damage, impaired autoregula-
tion, and excitotoxicity [31]. 
The goal of using NIV is to improve oxy-
genation, to decrease dyspnea and the work of 
breathing, and to avoid intubation [32]. It is belie-
ved to be beneficial because it recruits collapsed 
alveoli, increases the functional residual capacity, 
and decreases intrapulmonary shunt which, as 
a result, improves respiratory mechanics and gas 
exchange [33]. 
Hypoxemic ARF is usually defined as signifi-
cant hypoxemia (PaO2/FiO2 ≤ 200 mm Hg) and ta-
chypnea in a patient not diagnosed with COPD [4]. 
Thus, hypoxemic ARF represents the final result of 
a large number of different underlying pathologies 
[34]. Given the variety of the pathophysiology that 
leads to severe hypoxemia, drawing reasonable 
conclusions regarding the use of NIV for hypoxe-
mia is associated with significant challenges.
The Berlin definition for ARDS is as follows: 
mild when PaO2/FiO2 is > 200 and < 300 mm Hg; 
moderate when PaO2/FiO2 is > 100 and ≤ 200 mm 
Hg; and as severe when PaO2/FiO2 ≤ 100 mm Hg. 
Positive end-expiratory pressure (PEEP), which 
can be delivered through NIV, can markedly affect 
PaO2/FiO2. Therefore, a minimum level of PEEP 
(5 cm H2O) was added to the definition [35]. 
In the LUNG SAFE Study, 2813 patients with 
ARDS were managed with NIV or IMV irrespec-
tive of the severity category. In this study, NIV 
failure occurred in 37.5% of patients with ARDS 
and in almost half of patients with moderate and 
severe ARDS. NIV was associated with a worse 
adjusted ICU mortality than IMV in patients with 
a PaO2/FiO2 < 150 mm Hg. However, there was no 
difference in hospital mortality [36]. 
Additionally, a new concept of patient self- 
-inflicted lung injury can arise as spontaneous 
vigorous effort in non-intubated patients has 
been shown to worsen lung injury in moderate 
to severe ARDS. Higher EPAP through NIV can 
reduce the amount of atelectasis in the lung, de-
crease force generated by spontaneous effort, and 
often improves gas exchange. However, even in 
volume-controlled NIV mode, spontaneous effort 
can deteriorate lung injury by increasing local 
lung stress and overdistension [37]. 
As such, the use of NIV in patients with 
severe hypoxemic ARF is controversial [6, 38]. 
Most of the published literature has focused on 
common hypoxemic clinical conditions such as 
acute pulmonary edema and pneumonia [39]. 
Other investigations have focused on the use of 
NIV in severely hypoxemic patients due to ARDS 
[36, 40].
Current evidence for the use of NIV 
in hypoxemic ARF in patients 
with an altered level of consciousness
We reviewed published studies designed to 
assess the use of NIV as a first-line intervention 
in hypoxemic ARF to avoid ETI. However, the 
majority of studies excluded patients with altered 
levels of consciousness. Studies on altered men-
tal status due to primitive neurological diseases 
(e.g. stroke) or metabolic/toxic causes were not 
included (Figure 2, Table 2).
Only one study compared NIV efficacy in 
hypoxemic ARF in patients with an altered level 
of consciousness (GCS 9–14) versus patients with 
full awareness [41]. Patients were divided into two 
groups according to the presence (66 patients) or 
absence (82 patients) of encephalopathy. Patients 
with encephalopathy were older (median of 72 vs 
78 years, p = 0.02), had a higher APACHE II score 
(18 vs 19, p = 0.02), and received a higher level 
of IPAP. With the caveat of being a retrospective 
study with important baseline imbalances, there 
were no significant differences between groups 
in rates of NIV failure (24% vs 30%, p = 0.4) and 
in in-hospital mortality (13% vs 16%, p = 0.3).
Data from other studies must be cautiously 
taken into account as they did not exclude pa-
tients from their studies based simply on a cer-
tain level of awareness. Changes to the level of 
consciousness were not primary or secondary 
endpoints.
In a randomized clinical trial, Ferrer et al. 
[42] compared the efficacy of NIV versus the 
Venturi mask with FiO2 of 50% based on survival 
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and avoidance of ETI in 105 patients with GCS 
12–15 and hypoxemic ARF. After multivariate 
analysis, NIV was independently associated with 
a decreased risk of ETI (OR 0.20, p = 0.003) and 
90-day mortality (OR 0.39, p = 0.017).
In a study enrolling cardiogenic pulmonary 
edema patients with hypoxemic ARF who had 
a mildly altered level of consciousness (GCS 
8–15), CPAP significantly improved 48-hour 
mortality (7% vs 24%, p = 0.017) and reduced the 
need for intubation (9% vs 30%, p = 0.001). Ho-
wever, there was no improvement in in-hospital 
mortality compared to that of standard medical 
care [43].
Patel et al. conducted a study of ARDS pa-
tients with GCS 8–15 randomized to treatment 
with NIV delivered by helmet or face mask. Pa-
tients in the helmet (vs face mask) group showed 
a lower need for ETI (18.2% vs 61.5%, p < 0.001) 
and an improved survival rate at 90 days from 
randomization (34.1% vs 56.4%, p = 0.02) [44]. 
That being said, the helmet group had signifi-
cantly higher EPAP and lower pressure support 
results compared to the face mask group which 
may have influenced the final results. 
Hilbert et al. published a study comparing 
the use of NIV to standard treatment with sup-
plemental oxygen to treat immunosuppressed 
patients with hypoxemic ARF, including those 
with mildly altered levels of consciousness (GCS 
9–15). This study showed that NIV can obviate 
the need for ETI in this population (46% vs 77%, 
p = 0.03) and diminish in-hospital mortality rates 
(50% vs 81%, p = 0.02) [45]. 
In summary, the current literature is insuf-
ficient to address the efficacy of NIV compared 
to other treatments in patients with hypoxemic 
non-hypercapnic ARF who also have an altered 
level of consciousness.
Current evidence against the use of NIV 
in hypoxemic ARF in patients 
with an altered level of consciousness
Delayed intubation in patients undergoing 
trials of NIV can lead to increased mortality [46, 
47]. A previous study has reported a useful score 
(HACOR score) to predict NIV failure in patients 
with de novo hypoxemic ARF [48]. In this score, 
consciousness accounts for the highest weight 
among all risk factors for NIV failure. Patients 
with higher HACOR scores were more likely to 
experience NIV failure. Regarding consciousness, 
one assigns a HACOR score of 0 for GCS 15, 2 for 
Figure 2. Flowchart of the study selection process for using non-invasive ventilation in hypoxemic acute respiratory failure in patients with an 
altered level of consciousness
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Table 2. Current evidence for using NIV in hypoxemic ARF in patients with an altered level of consciousness
Author, year Patients and aim of 
the study
Level of 
consciousness
Type of study Results Limitations
Kogo 2018 [41] 148 patients, NIV effi-
cacy in mildly altered 
consciousness
GCS 9–14 vs GCS 15 Retrospective study No significant diffe-
rences in NIV failure 
and in-hospital mor-
tality
Retrospective study
Ferrer 2003 [42] 105 with severe ARF, 
NIV vs oxygen
GCS 12–15 Prospective, rando-
mized controlled. 
Compares oxygen 
with NIV
NIV improves oxyge-
nation, mortality, and 
decreases intubation 
rates
Difficulty for a correct 
blinding, relative 
heterogeneity of 
patients
L’Her 2004 [43] 89 patients with 
cardiogenic pulmo-
nary edema, CPAP vs 
standard treatment
GCS 8–15 Prospective, randomi-
zed, concealed,
and unblinded study
Reduction in early 48 
h-mortality and ETI
Blinding impossible
Patel 2016 [44] 83 patients with 
ARDS, helmet vs face 
mask
GCS 8–15 Single-center rando-
mized clinical trial
Reduction of intuba-
tion rates and 90-day 
mortality with helmet 
NIV
Blinding impossible
Hilbert 2001 [45] 52 immunosuppres-
sed patients, NIV vs 
standard treatment
GCS –15 Prospective, randomi-
zed trial
Reduction in ETI, 
serious complications 
and mortality
Blinding impossible, 
single unit
Duan 2017 [48] 358 patients in the 
validation cohort, 
develop a scale to 
predict NIV failure in 
hypoxemic ARF
GCS in NIV success 
14.8 ± 0.6 vs 14.3 ± 
1.6 in the NIV failure 
group
Prospective observa-
tional study
NIV failure was asso-
ciated with
lower GCS
Observational study
Thille 2013 [49] 113 patients, assess 
rates and predictive 
factors of NIV failure
GCS in NIV success 
14.9 ± 0.5 vs 14.6 ± 
1.2 in the NIV failure 
group
Observational cohort 
study
NIV failure was asso-
ciated with
lower GCS
Single unit with lon-
gstanding experience 
in the use of NIV
ARDS — acute respiratory distress syndrome; ARF — acute respiratory failure; CPAP — continuous positive airway pressure; ETI — endotracheal intubation; GCS 
— Glasgow coma scale; NIV — non-invasive ventilation
GCS 13–14, 5 for GCS 11–12, and 10 for GCS ≤ 
10. In this study, in patients with a HACOR score 
> 5, the risk for NIV failure reached up to 80%. 
Thus, the use of NIV in patients with low levels 
of consciousness must be done cautiously, espe-
cially in those with GCS ≤ 10. 
In an observational cohort study, Thille et 
al. [49] assessed the rates and predictive factors 
of NIV failure in patients admitted to the ICU for 
hypoxemic ARF. Among 113 patients receiving 
NIV, 82 had ARDS and 31 had non-ARDS. Intu-
bation rates significantly differed between ARDS 
and non-ARDS patients (61% vs 35%, p = 0.015) 
according to the clinical severity of ARDS. NIV 
failure was associated with active cancer, shock, 
moderate/severe ARDS, lower EPAP at NIV initia-
tion, and lower GCS (p = 0.018).
In fact, the latest ERS/ATS clinical practice 
guidelines for NIV do not offer a recommendation 
about NIV use for de novo hypoxemic ARF [4]. 
This is justified, firstly, by the fact that as soon 
as NIV is ceased, the positive effects previously 
gained in terms of alveolar recruitment and 
oxygenation are lost. Secondly, during NIV, tidal 
volume results from the pressures given by the 
ventilator coupled with the respiratory muscle 
pressure generated by the patient’s respiratory 
drive. Due to this mechanism, tidal volume is 
often high and may trigger ventilator-induced 
lung injury which contrasts with the intended 
lung protective ventilation strategies (low tidal 
volume of 6 mL/kg of predicted body weight) [32]. 
Finally, in a randomized controlled trial, the use 
of high-flow nasal cannula therapy has shown 
benefit in patient survival when compared with 
NIV and standard oxygen therapy in the treatment 
of hypoxemic ARF [50]. 
Conclusion
The overall analysis of the studies reviewed 
support the use of NIV as an adjunctive therapy 
in patients with hypercapnic encephalopathy 
because it decreases complication rates, the 
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Table 3. Advantages and disadvantages for using NIV over IMV in hypercapnic ARF encephalopathy
Advantages Disadvantages
Less complication rates Benefits decrease with lower levels of consciousness
Less cost Benefits more significant in acute pulmonary edema, COPD, 
and obesity rather than ARDS or pneumoniaLess hospital and ICU length of stay
Less mortality
ARDS — acute respiratory distress syndrome; COPD — chronic obstructive pulmonary disease; ICU — intensive care unit
Table 4. Advantages and disadvantages for using NIV over IMV in hypoxemic ARF in patients with an altered level of con-
sciousness 
Advantages Disadvantages
Less complication rates NIV failure associated with active cancer, shock, moderate/severe ARDS
Lower EPAP at NIV initiation and lower GCS
Less cost Higher risk of NIV failure when GCS ≤ 10
ARDS — acute respiratory distress syndrome; EPAP — expiratory positive airway pressure; GCS — Glasgow coma scale; NIV — non-invasive ventilation
need for ETI, hospital length of stay, and mor-
tality rate when compared to IMV. Patients with 
hypercapnic ARF and impaired consciousness 
can be treated with NIV, however, these results 
appear to be more relevant to specific patient po-
pulations including those with acute pulmonary 
edema, COPD, and obesity rather than conditions 
such as ARDS or pneumonia. Close monitoring 
is also mandatory as improvements in blood gas 
percentages within the first hours correlate with 
NIV success (Table 3).
Data regarding NIV effectiveness in hy-
poxemic ARF patients with an altered level of 
consciousness are more controversial given the 
heterogeneity of the studies identified and the 
fact that many studies excluded patients with 
alterations in mental status. Based on the exami-
ned studies, there is no evidence to either support 
or reject the routine use of NIV in patients with 
hypoxemic altered levels of consciousness due 
to ARF. However, NIV failure seems to increase 
with declining levels of consciousness. A multi-
center, randomized, and controlled study trial is 
needed to clarify whether a benefit of NIV exists 
compared to other supportive treatments with 
regard to clinically important outcomes such as 
intubation rate, mortality, hospital/ICU length of 
stay, and other patient-centered outcome measu-
res (Table 4).
In all cases, increased clinical experience 
in administering NIV, patient tolerance, and 
selection of the most appropriate interfaces are 
important considerations. The clinical status of 
the patient must be carefully monitored during 
NIV application. Clinicians must ensure that the 
use of NIV does not delay the need for ETI in pa-
tients who are deteriorating during NIV treatment. 
Proper patient monitoring is critical to ensure safe 
NIV initiation and titration. Skills in NIV appli-
cation and limiting its use to highly monitored 
clinical settings are critical factors to consider 
to ensure optimal use of NIV and patient safety.
Conflict of interest
None declared.
References:
1. Keenan SP, Sinuff T, Cook DJ, et al. Which patients with acute 
exacerbation of chronic obstructive pulmonary disease benefit 
from noninvasive positive-pressure ventilation? A systema-
tic review of the literature. Ann Intern Med. 2003; 138(11): 
861–870, doi: 10.7326/0003-4819-138-11-200306030-00007, 
indexed in Pubmed: 12779296.
2. Lightowler JV, Wedzicha JA, Elliott MW, et al. Non-invasive 
positive pressure ventilation to treat respiratory failure re-
sulting from exacerbations of chronic obstructive pulmonary 
disease: Cochrane systematic review and meta-analysis. BMJ. 
2003; 326(7382): 185, doi: 10.1136/bmj.326.7382.185, indexed 
in Pubmed: 12543832.
3. Lopez-Campos JL, Garcia Polo C, Leon Jimenez A, et al. Staff 
training influence on non-invasive ventilation outcome for 
acute hypercapnic respiratory failure. Monaldi Arch Chest Dis. 
2006; 65(3): 145–151, doi: 10.4081/monaldi.2006.560, indexed 
in Pubmed: 17220104.
4. Rochwerg B, Brochard L, Elliott MW, et al. Official ERS/
ATS clinical practice guidelines: noninvasive ventilation 
for acute respiratory failure. Eur Respir J. 2017; 50(2), doi: 
10.1183/13993003.02426-2016, indexed in Pubmed: 28860265.
5. Chawla R, Dixit SB, Zirpe KG, et al. ISCCM guidelines for the 
use of non-invasive ventilation in acute respiratory failure in 
adult icus. Indian J Crit Care Med. 2020; 24(Suppl 1): S61–S81, 
Gil Gonçalves et al., Non-invasive ventilation in patients with an altered level of consciousness
243www.journals.viamedica.pl
doi: 10.5005/jp-journals-10071-G23186, indexed in Pubmed: 
32205957.
6. Antonelli M, Conti G, Rocco M, et al. A comparison of no-
ninvasive positive-pressure ventilation and conventional 
mechanical ventilation in patients with acute respiratory fa-
ilure. N Engl J Med. 1998; 339(7): 429–435, doi: 10.1056/
NEJM199808133390703, indexed in Pubmed: 9700176.
7. Mehta S, Hill NS. Noninvasive ventilation. Am J Respir 
Crit Care Med. 2001; 163(2): 540–577, doi: 10.1164/aj-
rccm.163.2.9906116, indexed in Pubmed: 11179136.
8. Evans TW. International Consensus Conferences in icine: non
-invasive positive pressure ventilation in acute respiratory 
failure. Organised jointly by the American Thoracic Society, 
the European Respiratory Society, the European Society of 
icine, and the Societe de Reanimation de Langue Francaise, 
and approved by the ATS Board of Directors, December 2000. 
Intensive Care Med. 2001; 27(1): 166–178.
9. Teasdale G, Jennett B. Assessment of coma and impaired con-
sciousness. A practical scale. Lancet. 1974; 2(7872): 81–84, 
doi: 10.1016/s0140-6736(74)91639-0, indexed in Pubmed: 
4136544.
10. Kelly BJ, Matthay MA. Prevalence and severity of neurolo-
gic dysfunction in critically ill patients. Influence on need 
for continued mechanical ventilation. Chest. 1993; 104(6): 
1818–1824, doi: 10.1378/chest.104.6.1818, indexed in Pub-
med: 8252971.
11. Scala R. Hypercapnic encephalopathy syndrome: a new fron-
tier for non-invasive ventilation? Respir Med. 2011; 105(8): 
1109–1117, doi: 10.1016/j.rmed.2011.02.004, indexed in Pub-
med: 21354774.
12. Honrubia T, García López FJ, Franco N, et al. Noninvasive vs 
conventional mechanical ventilation in acute respiratory fa-
ilure: a multicenter, randomized controlled trial. Chest. 2005; 
128(6): 3916–3924, doi: 10.1378/chest.128.6.3916, indexed in 
Pubmed: 16354864.
13. Gay PC. Complications of noninvasive ventilation in acute 
care. Respir Care. 2009; 54(2): 246--258.
14. Bitnar P, Stovicek J, Andel R, et al. Leg raise increases pressure 
in lower and upper esophageal sphincter among patients with 
gastroesophageal reflux disease. J Bodyw Mov Ther. 2016; 
20(3): 518–524, doi: 10.1016/j.jbmt.2015.12.002, indexed in 
Pubmed: 27634073.
15. Pandolfino JE, Gawron AJ. Achalasia: a systematic re-
view. JAMA. 2015; 313(18): 1841–1852, doi: 10.1001/
jama.2015.2996, indexed in Pubmed: 25965233.
16. Lemyze M, De Palleja G, Guiot A, et al. Outcome of frail 
do-not-intubate subjects with end-stage chronic respiratory 
failure and their opinion of noninvasive ventilation to reverse 
hypercapnic coma. Respir Care. 2019; 64(9): 1023–1030, doi: 
10.4187/respcare.06346, indexed in Pubmed: 30890633.
17. Mas A, Masip J. Noninvasive ventilation in acute respiratory 
failure. Int J Chron Obstruct Pulmon Dis. 2014; 9: 837–852, 
doi: 10.2147/COPD.S42664, indexed in Pubmed: 25143721.
18. Corrado A, De Paola E, Gorini M, et al. Intermittent negative 
pressure ventilation in the treatment of hypoxic hypercap-
nic coma in chronic respiratory insufficiency. Thorax. 1996; 
51(11): 1077–1082, doi: 10.1136/thx.51.11.1077, indexed in 
Pubmed: 8958888.
19. Briones Claudett KH, Briones Claudett MH, Chung Sang 
Wong MA, et al. Noninvasive mechanical ventilation in pa-
tients with chronic obstructive pulmonary disease and seve-
re hypercapnic neurological deterioration in the emergency 
room. Eur J Emerg Med. 2008; 15(3): 127–133, doi: 10.1097/
MEJ.0b013e3282f08d08, indexed in Pubmed: 18460951.
20. Díaz GG, Alcaraz AC, Talavera JC, et al. Noninvasive positive
-pressure ventilation to treat hypercapnic coma secondary to 
respiratory failure. Chest. 2005; 127(3): 952–960, doi: 10.1378/
chest.127.3.952, indexed in Pubmed: 15764781.
21. Scala R, Nava S, Conti G, et al. Noninvasive versus conventio-
nal ventilation to treat hypercapnic encephalopathy in chronic 
obstructive pulmonary disease. Intensive Care Med. 2007; 
33(12): 2101–2108, doi: 10.1007/s00134-007-0837-2, indexed 
in Pubmed: 17874232.
22. Zhu Gf, Zhang W, Zong H, et al. Effectiveness and safety of 
noninvasive positive-pressure ventilation for severe hyper-
capnic encephalopathy due to acute exacerbation of chronic 
obstructive pulmonary disease: a prospective case-control stu-
dy. Chin Med J (Engl). 2007; 120(24): 2204–2209, indexed in 
Pubmed: 18167203.
23. Chandra D, Stamm JA, Taylor B, et al. Outcomes of noninva-
sive ventilation for acute exacerbations of chronic obstructive 
pulmonary disease in the United States, 1998-2008. Am J 
Respir Crit Care Med. 2012; 185(2): 152–159, doi: 10.1164/
rccm.201106-1094OC, indexed in Pubmed: 22016446.
24. Stefan MS, Nathanson BH, Higgins TL, et al. Comparative 
effectiveness of noninvasive and invasive ventilation in criti-
cally ill patients with acute exacerbation of chronic obstructive 
pulmonary disease. Crit Care Med. 2015; 43(7): 1386–1394, 
doi: 10.1097/CCM.0000000000000945, indexed in Pubmed: 
25768682.
25. Confalonieri M, Garuti G, Cattaruzza MS, et al. Italian noni-
nvasive positive pressure ventilation (NPPV) study group. A 
chart of failure risk for noninvasive ventilation in patients 
with COPD exacerbation. Eur Respir J. 2005; 25(2): 348–355, 
doi: 10.1183/09031936.05.00085304, indexed in Pubmed: 
15684302.
26. Fan L, Zhao Q, Liu Y, et al. Semiquantitative cough strength 
score and associated outcomes in noninvasive positive pressu-
re ventilation patients with acute exacerbation of chronic 
obstructive pulmonary disease. Respir Med. 2014; 108(12): 
1801–1807, doi: 10.1016/j.rmed.2014.10.001, indexed in Pub-
med: 25459451.
27. Wang J, Cui Z, Liu S, et al. Early use of noninvasive techniques 
for clearing respiratory secretions during noninvasive positi-
ve-pressure ventilation in patients with acute exacerbation of 
chronic obstructive pulmonary disease and hypercapnic ence-
phalopathy: A prospective cohort study. Medicine (Baltimore). 
2017; 96(12): e6371, doi: 10.1097/MD.0000000000006371, in-
dexed in Pubmed: 28328824.
28. Scala R, Naldi M, Maccari U. Early fiberoptic bronchoscopy 
during non-invasive ventilation in patients with decompen-
sated chronic obstructive pulmonary disease due to commu-
nity-acquired-pneumonia. Crit Care. 2010; 14(2): R80, doi: 
10.1186/cc8993, indexed in Pubmed: 20429929.
29. Scala R. Non-invasive ventilation in acute respiratory failure 
with altered consciousness syndrome: a bargain or an hazard? 
Minerva Anestesiol. 2013; 79(11): 1291–1299, indexed in Pub-
med: 23719655.
30. Huang Z, Chen Ys, Yang Zl, et al. Dexmedetomidine versus 
midazolam for the sedation of patients with non-invasive 
ventilation failure. Intern Med. 2012; 51(17): 2299–2305, 
doi: 10.2169/internalmedicine.51.7810, indexed in Pubmed: 
22975538.
31. Tauber SC, Eiffert H, Brück W, et al. Fungal encephalitis in 
human autopsy cases is associated with extensive neuronal 
damage but only minimal repair. Neuropathol Appl Neuro-
biol. 2014; 40(5): 610–627, doi: 10.1111/nan.12044, indexed 
in Pubmed: 23517274.
32. Scala R, Pisani L. Noninvasive ventilation in acute respira-
tory failure: which recipe for success? Eur Respir Rev. 2018; 
27(149), doi: 10.1183/16000617.0029-2018, indexed in Pub-
med: 29997247.
33. Bello G, De Pascale G, Antonelli M, et al. Noninvasive ventila-
tion for the immunocompromised patient: always appropria-
te? Curr Opin Crit Care. 2012; 18(1): 54–60, doi: 10.1097/
MCC.0b013e32834e7c21, indexed in Pubmed: 22143051.
34. Narendra DK, Hess DR, Sessler CN, et al. Update in manage-
ment of severe hypoxemic respiratory failure. Chest. 2017; 
152(4): 867–879, doi: 10.1016/j.chest.2017.06.039, indexed in 
Pubmed: 28716645.
35. Ranieri VM, Rubenfeld GD, Thompson BT, et al. ARDS De-
finition Task Force. Acute respiratory distress syndrome: 
the Berlin Definition. JAMA. 2012; 307(23): 2526–2533, doi: 
10.1001/jama.2012.5669, indexed in Pubmed: 22797452.
36. Bellani G, Laffey JG, Pham T, et al. LUNG SAFE Investiga-
tors, ESICM Trials Group. Noninvasive ventilation of patients 
with acute respiratory distress syndrome. Insights from the 
LUNG SAFE study. Am J Respir Crit Care Med. 2017; 195(1): 
67–77, doi: 10.1164/rccm.201606-1306OC, indexed in Pub-
med: 27753501.
Advances in Respiratory Medicine 2020, vol. 88, no. 3, pages 233–244
244 www.journals.viamedica.pl
37. Yoshida T, Grieco DL, Brochard L, et al. Patient self-inflicted 
lung injury and positive end-expiratory pressure for safe spon-
taneous breathing. Curr Opin Crit Care. 2020; 26(1): 59–65, 
doi: 10.1097/MCC.0000000000000691, indexed in Pubmed: 
31815775.
38. Xu XP, Zhang XC, Hu SL, et al. Noninvasive ventilation in 
acute hypoxemic nonhypercapnic respiratory failure: a syste-
matic review and meta-analysis. Crit Care Med. 2017; 45(7): 
e727–e733, doi: 10.1097/CCM.0000000000002361, indexed in 
Pubmed: 28441237.
39. Antonelli M, Conti G, Moro ML, et al. Predictors of failure 
of noninvasive positive pressure ventilation in patients with 
acute hypoxemic respiratory failure: a multi-center study. 
Intensive Care Med. 2001; 27(11): 1718–1728, doi: 10.1007/
s00134-001-1114-4, indexed in Pubmed: 11810114.
40. Bernard GR, Artigas A, Brigham KL, et al. Report of the Ameri-
can-European consensus conference on ARDS: definitions, me-
chanisms, relevant outcomes and clinical trial coordination. The 
Consensus Committee. Intensive Care Med. 1994; 20(3): 225–
232, doi: 10.1007/BF01704707, indexed in Pubmed: 8014293.
41. Kogo M, Nagata K, Morimoto T, et al. What is the impact of 
mildly altered consciousness on acute hypoxemic respirato-
ry failure with non-invasive ventilation? Intern Med. 2018; 
57(12): 1689–1695, doi: 10.2169/internalmedicine.9355-17, 
indexed in Pubmed: 29434147.
42. Ferrer M, Esquinas A, Leon M, et al. Noninvasive ventilation 
in severe hypoxemic respiratory failure: a randomized clinical 
trial. Am J Respir Crit Care Med. 2003; 168(12): 1438–1444, doi: 
10.1164/rccm.200301-072OC, indexed in Pubmed: 14500259.
43. L’Her E, Duquesne F, Girou E, et al. Noninvasive continuous 
positive airway pressure in elderly cardiogenic pulmonary 
edema patients. Intensive Care Med. 2004; 30(5): 882–888, doi: 
10.1007/s00134-004-2183-y, indexed in Pubmed: 14991092.
44. Patel BK, Wolfe KS, Pohlman AS, et al. Effect of noninvasi-
ve ventilation delivered by helmet vs face mask on the rate 
of endotracheal intubation in patients with acute respiratory 
distress syndrome: a randomized clinical trial. JAMA. 2016; 
315(22): 2435–2441, doi: 10.1001/jama.2016.6338, indexed in 
Pubmed: 27179847.
45. Hilbert G, Gruson D, Vargas F, et al. Noninvasive ventilation 
in immunosuppressed patients with pulmonary infiltrates, 
fever, and acute respiratory failure. N Engl J Med. 2001; 344(7): 
481–487, doi: 10.1056/NEJM200102153440703, indexed in 
Pubmed: 11172189.
46. Esteban A, Frutos-Vivar F, Ferguson ND, et al. Noninvasive 
positive-pressure ventilation for respiratory failure after extu-
bation. N Engl J Med. 2004; 350(24): 2452–2460, doi: 10.1056/
NEJMoa032736, indexed in Pubmed: 15190137.
47. Kikuchi T, Toba S, Sekiguchi Y, et al. Protocol-based noninva-
sive positive pressure ventilation for acute respiratory failure. 
J Anesth. 2011; 25(1): 42–49, doi: 10.1007/s00540-010-1051-x, 
indexed in Pubmed: 21153036.
48. Duan J, Han X, Bai L, et al. Assessment of heart rate, acidosis, 
consciousness, oxygenation, and respiratory rate to predict 
noninvasive ventilation failure in hypoxemic patients. Inten-
sive Care Med. 2017; 43(2): 192–199, doi: 10.1007/s00134-016-
4601-3, indexed in Pubmed: 27812731.
49. Thille AW, Contou D, Fragnoli C, et al. Non-invasive ventila-
tion for acute hypoxemic respiratory failure: intubation rate 
and risk factors. Crit Care. 2013; 17(6): R269, doi: 10.1186/
cc13103, indexed in Pubmed: 24215648.
50. Coudroy R, Frat JP, Ehrmann S, et al. REVA Network, REVA 
network, FLORALI Study Group, REVA Network. High-flow 
oxygen through nasal cannula in acute hypoxemic respiratory 
failure. N Engl J Med. 2015; 372(23): 2185–2196, doi: 10.1056/
NEJMoa1503326, indexed in Pubmed: 25981908.
51. Contou D, Fragnoli C, Córdoba-Izquierdo A, et al. Noninvasive 
ventilation for acute hypercapnic respiratory failure: intuba-
tion rate in an experienced unit. Respir Care. 2013; 58(12): 
2045–2052, doi: 10.4187/respcare.02456, indexed in Pubmed: 
23737546.
52. Briones Claudett KH, Briones Claudett M, Chung Sang Wong 
M, et al. Noninvasive mechanical ventilation with average 
volume assured pressure support (AVAPS) in patients with 
chronic obstructive pulmonary disease and hypercapnic ence-
phalopathy. BMC Pulm Med. 2013; 13: 12, doi: 10.1186/1471-
2466-13-12, indexed in Pubmed: 23497021.
53. Scala R, Naldi M, Archinucci I, et al. Noninvasive positi-
ve pressure ventilation in patients with acute exacerbations 
of COPD and varying levels of consciousness. Chest. 2005; 
128(3): 1657–1666, doi: 10.1378/chest.128.3.1657, indexed in 
Pubmed: 16162772.
54. Jatoi S, Akhter S, Rizvi N, et al. Standard factors predicting 
success of Non-invasive ventilation are useful in treating Pa-
tients with POST Tuberculosis sequel. J Pak Med Assoc. 2019; 
69(8): 1146–1149, indexed in Pubmed: 31431769.
55. Scarpazza P, Incorvaia C, Melacini C, et al. Shrinking the room 
for invasive ventilation in hypercapnic respiratory failure. Int 
J Chron Obstruct Pulmon Dis. 2013; 8: 135–137, doi: 10.2147/
COPD.S41374, indexed in Pubmed: 23516004.
56. van Gemert JP, Brijker F, van Gemert JP, et al. Intubation after 
noninvasive ventilation failure in chronic obstructive pulmo-
nary disease: associated factors at emergency department pre-
sentation. Eur J Emerg Med. 2015; 22(1): 49–54, doi: 10.1097/
MEJ.0000000000000141, indexed in Pubmed: 24637440.
57. Ucgun I, Metintas M, Moral H, et al. Predictors of hospital 
outcome and intubation in COPD patients admitted to the re-
spiratory ICU for acute hypercapnic respiratory failure. Respir 
Med. 2006; 100(1): 66–74, doi: 10.1016/j.rmed.2005.04.005, 
indexed in Pubmed: 15890508.
58. Kida Y, Minakata Y, Yamada Y, et al. Efficacy of noninvasive 
positive pressure ventilation in elderly patients with acute 
hypercapnic respiratory failure. Respiration. 2012; 83(5): 377–
382, doi: 10.1159/000328399, indexed in Pubmed: 21734354.
